The PLCO and ERSPC trials have reported the long-term effects on prostate cancer mortality of PSA-based screening approaches; however, a number of controversies remain in this field. Here, Strope and Andriole discuss and interpret the results of these trials, and suggest how PSA-based screening can be improved upon in the future.
- Seth A. Strope
- Gerald L. Andriole
